中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

116 records (took 0.025 seconds)

    (POLYALKOXY)SULFONATE SURFACE MODIFIERS
    1.
    发明申请
    (POLYALKOXY)SULFONATE SURFACE MODIFIERS 审中-公开
    （聚烷氧基）磺酸盐表面改性剂

    公开(公告)号：WO2006081000A9

    公开(公告)日：2006-08-31

    申请号：PCT/US2005045321

    申请日：2005-12-15

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  KIPP JAMES E ,  HAI TON THAT ,  MELNICK BENNETT P

    Inventor： KIPP JAMES E ,  HAI TON THAT ,  MELNICK BENNETT P

    IPC: C08G65/326 ,  C08G65/334 ,  C08L71/02

    CPC classification number: C08G65/334 ,  A61K8/90 ,  A61K9/146 ,  A61K47/34 ,  A61Q19/00 ,  C08G65/326 ,  C08L71/02

    Abstract: The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised of a non-polar polyether covalently linked to an anionic sulfonate group. The compounds have an amphipathic quality and preferably, are surface active. Such compounds are preferably useful as surface-active agents to coat and stabilize dispersions of particles in a continuous liquid medium. These surface-active agents may be applied in the stabilization of suspensions, emulsions, or liposome formulations intended for pharmaceutical, medical, cosmetic, or agricultural use. The particles that can be prepared by a variety of methods and will preferably comprise a pharmaceutical agent. Pharmaceutical compositions of the present invention can be used to treat amyriad of conditions and can be administered by many routes, including intravenous, intramuscular, subcutaneous, intrathecal, subdural, intracameral, intracerebral, intralesional, topical, oral, buccal, rectal, pulmonary, and nasal.

    Abstract translation: 本发明涉及新型化合物，制造方法和使用方法。 本发明还涉及具有与其表面结合的一种或多种本发明化合物的固体药物/活性剂颗粒。 本发明的化合物由与阴离子磺酸盐基团共价连接的非极性聚醚组成。 这些化合物具有两亲性，并且优选具有表面活性。 这些化合物优选用作表面活性剂以涂覆和稳定连续液体介质中的颗粒分散体。 这些表面活性剂可以用于稳定用于药物，医学，化妆品或农业用途的悬浮液，乳液或脂质体制剂。 可以通过多种方法制备并且优选包含药剂的颗粒。 本发明的药物组合物可用于治疗多种病症，并可通过多种途径给药，包括静脉内，肌肉内，皮下，鞘内，硬膜下，前房内，脑内，病灶内，局部，口服，口腔，直肠，肺和 鼻。

    MAGNETIC SEPARATION OF FINE PARTICLES FROM COMPOSITIONS
    2.
    发明申请
    MAGNETIC SEPARATION OF FINE PARTICLES FROM COMPOSITIONS 审中-公开
    从组合物中精细分离细颗粒的磁分离

    公开(公告)号：WO2008080047A3

    公开(公告)日：2008-08-14

    申请号：PCT/US2007088527

    申请日：2007-12-21

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  KIPP JAMES E ,  WONG JOSEPH CHUNG TAK ,  WERLING JANE O

    Inventor： KIPP JAMES E ,  WONG JOSEPH CHUNG TAK ,  WERLING JANE O

    IPC: B03C1/28

    CPC classification number: B03C1/288

    Abstract: The disclosure describes apparatuses and methods of use thai may be used to remove material with magnetic properties from compositions, particularly pharmaceutical compositions. The apparatuses provide a conduit or column in which a magnetic field exists and through which a composition flows. Magnetic material in the composition is substantially reduced after flowing through the conduit or column.

    Abstract translation: 本公开描述了可以用于从组合物，特别是药物组合物中去除具有磁性的材料的装置和方法。 这些装置提供了一种导管或立柱，其中存在磁场并且组合物通过该磁场流动。 组合物中的磁性材料在流过导管或柱之后显着降低。

    EX-VIVO APPLICATION OF SOLID MICROPARTICULATE THERAPEUTIC AGENTS
    4.
    发明申请
    EX-VIVO APPLICATION OF SOLID MICROPARTICULATE THERAPEUTIC AGENTS 审中-公开
    固体微粒治疗药物的实例应用

    公开(公告)号：WO2005123907A3

    公开(公告)日：2007-08-23

    申请号：PCT/US2005022992

    申请日：2005-06-08

    Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  KIPP JAMES E ,  RABINOW BARRETT E

    Inventor： KIPP JAMES E ,  RABINOW BARRETT E

    IPC: C12N5/06 ,  A61K9/14 ,  A61K35/12 ,  A61K45/00 ,  A61K47/48 ,  A61K49/00

    CPC classification number: A61K49/0002 ,  A61K9/14 ,  A61K35/12 ,  A61K47/6901 ,  A61K2035/124

    Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations threof. After administration, the loaded cells transport the pharmaceutical composition as particles.

    Abstract translation: 本发明涉及制备和递送药物活性物质的小颗粒到哺乳动物受试者中用于治疗疾病或病症的方法。 优选的实施方案包括：（i）从动物供体收集组织细胞，（ii）这些细胞在细胞培养基中的选择性或非选择性生长，其中加入主要不含 药物载体（约10重量％或更少，重量百分比），平均粒径小于约100微米，（iii）使细胞培养基中的细胞与治疗活性化合物的固体颗粒接触， 被细胞吸收到培养细胞的细胞内隔室中，将活性化合物作为颗粒附着到这种细胞的周边，或细胞内摄取和附着到细胞表面的组合，（iv）任选的分离和 /或在步骤i至iii中制备的细胞的再悬浮，（v）向哺乳动物受试者施用细胞。 药物活性物质可以通过静脉内，肌肉内，皮下，皮内，关节内，鞘内，硬膜外，脑内，经口颊途径，直肠，局部，经皮，口服，鼻内，经由肺途径，腹膜内或组合Threof施用。 给药后，加载的细胞将药物组合物作为颗粒运输。

    METHODS FOR THE COMMINUTION AND STABILIZATION OF SMALL PARTICLES IN SUSPENSION
    5.
    发明申请
    METHODS FOR THE COMMINUTION AND STABILIZATION OF SMALL PARTICLES IN SUSPENSION 审中-公开
    小颗粒悬浮液的制备和稳定化方法

    公开(公告)号：WO2004084860A3

    公开(公告)日：2005-03-24

    申请号：PCT/US2004009242

    申请日：2004-03-24

    Applicant: BAXTER INT

    Inventor： KIPP JAMES E ,  WONG JOSEPH CHUNG TAK ,  WISLER MONTE ,  GARCIA RHONDA

    IPC: A61K9/10 ,  A61K9/14

    CPC classification number: A61K9/145 ,  A61K9/10 ,  Y10S516/924 ,  Y10S516/925 ,  Y10S977/84

    Abstract: Methods and apparatuses for comminuting and stabilizing small particles are provided. In one embodiment, an apparatus moves an organic compound dissolved in a solvent to form a suspension of particles in a first fluid stream and moves the suspension in a second fluid stream, wherein the second fluid stream is oriented and positioned with respect to the first stream to cause shearing between the streams and mixing of at least some of the particles in the first and second streams.

    Abstract translation: 提供粉碎和稳定小颗粒的方法和装置。 在一个实施方案中，装置移动溶解在溶剂中的有机化合物以形成第一流体物流中的颗粒悬浮液并将悬浮液移动到第二流体流中，其中第二流体流相对于第一流定向和定位 以引起流之间的剪切和第一和第二流中的至少一些颗粒的混合。

    PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE
    8.
    发明申请
    PREPARATION OF SUBMICRON SIZED PARTICLES WITH POLYMORPH CONTROL AND NEW POLYMORPH OF ITRACONAZOLE 审中-公开
    具有聚合物控制和新戊酰胺的新型聚合物的亚型尺寸颗粒的制备

    公开(公告)号：WO2004054500A3

    公开(公告)日：2004-08-26

    申请号：PCT/US0324353

    申请日：2003-08-04

    Applicant: BAXTER INT

    Inventor： WERLING JANE ,  KIPP JAMES E ,  SRIRAM RAJARAM ,  DOTY MARK J ,  REBBECK CHRISTINE L ,  WONG JOSEPH CHUNG TAK

    IPC: A61K9/00 ,  A61K31/495 ,  A61K9/127 ,  A61K9/14

    CPC classification number: A61K9/14 ,  A61K9/0019 ,  A61K9/10 ,  A61K31/495

    Abstract: The present invention provides a method of preparing particles with polymorph and size control of a pharmaceutical compound, the method including the steps of: (1) providing pharmaceutical compound in a first phase; (2) seeding the compound; (3) causing a phase change in the pharmaceutical compound to a second phase of a desired polymorphic form; and (4) wherein the mean particle size of the particles is less than 7µm. The present invention further provides a polymorphic form of itraconazole.

    Abstract translation: 本发明提供一种制备具有药物化合物的多晶型物和粒度控制的颗粒的方法，所述方法包括以下步骤：（1）在第一相中提供药物化合物; （2）接种化合物; （3）引起药物化合物相变为所需多晶型物的第二相; 和（4）其中颗粒的平均粒度小于7μm。 本发明还提供了伊曲康唑的多晶型物。

    PREMIXED AMIODARONE PARENTERAL SOLUTION AND METHOD FOR MAKING THE SAME
    9.
    发明申请
    PREMIXED AMIODARONE PARENTERAL SOLUTION AND METHOD FOR MAKING THE SAME 审中-公开
    预先使用的AMIODARONE公司解决方案及其制备方法

    公开(公告)号：WO02078605A3

    公开(公告)日：2003-02-06

    申请号：PCT/US0210094

    申请日：2002-03-28

    Applicant: BAXTER INT

    Inventor： DOTY MARK J ,  REBBECK CHRISTINE L ,  KIPP JAMES E ,  RAGHAVAN NEERVALUR V

    IPC: C07D307/80 ,  A61K9/00 ,  A61K9/08 ,  A61K31/343 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34 ,  A61K47/36 ,  A61P9/06

    CPC classification number: A61K9/0019 ,  A61K31/343 ,  A61K47/26

    Abstract: A premix parenteral solution for intravenous administration having amiodarone, as an active ingredient, solubilized in a solution of water for injection and about 0.4 - 12 mg/ml of a non-ionic surfactant to a concentration range of from 0.2 to 6 mg/ml is disclosed. The solution optionally may include an osmotic agent. No dilution of the solution is required before administering to a patient and the sterile packaged solution has an initial pH within the range of from about 2.9 to about 3.2, preferably about 3.1. Additionally, a method for producing an amiodarone solution suitable for intravenous administration is further disclosed.

    Abstract translation: 用于静脉内给药的预混合肠胃外溶液，其具有溶解于注射用水和约0.4-12mg / ml非离子表面活性剂的胺碘酮作为活性成分，浓度范围为0.2至6mg / ml， 披露。 溶液任选地可以包括渗透剂。 在给予患者之前不需要稀释溶液，无菌包装溶液的初始pH范围为约2.9至约3.2，优选约3.1。 此外，还公开了适用于静脉内给药的胺碘酮溶液的制备方法。

Patent Agency Ranking